Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension

NCT01523067 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.

NCT NCT01523067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01523067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
December 31, 2012
Enrollment
68 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension